Navigation Links
Reportlinker Adds Biomarkers - Technologies, Markets and Companies
Date:6/3/2010

Monoclonal antibodies 33

Bavituximab 34

Treatment of viral infection with radiolabeled MAbs 34

Limitations of MAbs and measures to overcome these 35

Interferon-based approaches 35

Novel antiviral approaches 35

Synthetic modified hypericin compounds 35

Targeting Toll-like receptors 36

Potential and drawbacks of TLR-ligands in viral diseases 37

Inhibition of viral transport from cytoplasm into the cell nucleus 37

Nitric Oxide based antiviral therapeutics 37

Gene therapy for viral infections 38

Antisense approaches to viral infections 38

Antisense oligonucleotides 38

Limitations of antisense oligonucleotides as antivirals 39

NEUGENE antisense 39

RNAi screens of viral genomes 40

RNAi for treatment of viral infections 40

Promise and pitfalls of RNAi gene therapy 42

Management of rapidly evolving pathogens 42

Personalized medicine and viral diseases 43

An integrated approach to viral diseases 43

Current problems and needs in antiviral therapy 43

3. Vaccines for Virus Infections 45

Introduction 45

Types of vaccines 46

Live attenuated virus vaccines 46

DNA vaccines 46


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related biology technology :

1. Reportlinker Adds Future of Red Biotechnology in China
2. Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration
3. Reportlinker Adds the Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles)
4. Reportlinker Adds SNP Genotyping and Analysis Markets
5. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
6. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
7. Reportlinker Adds Biotechnology Instrumentation - International Market Trends
8. Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective
9. Reportlinker Adds Pharmacodynamic Assays
10. Reportlinker Adds Neurostimulation - A Global Market Perspective
11. Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Kingston, Ontario (PRWEB) May 21, 2015 ... entered into an exclusive North American distribution agreement ... microbiology testing system. , With more than 160 ... of products and services for laboratory and production ... choice, operational excellence and differentiated services to enable ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 This ... history, especially for lawns. US Patented Pearl’s Premium ... for lawns around the country that are coming out ... that addresses a number of major global concerns related ... the “non-grass” grass – the alternative to the standard, ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
... report commissioned by the U.S. Department of Energy has ... of producing hydrogen fuel from sunlight is the only ... meet future cost targets set by the federal agency. ... Alan Weimer,s research team of CU-Boulder,s chemical and biological ...
... Stem Cell Assurance, Inc. (SCLZ.PK) announced today ... Securities on Form 10 pursuant to Section 12(g) of the ... financial statements as of December 31, 2009 and 2010 and ... July 11, 2011, the Company will become an SEC reporting ...
... Dan Neumeister, FACHE, principal of Neumeister Healthcare Management Services ... selected by Chase Brexton Health Services (CBHS) of Baltimore, ... effective May 1, 2011. Neumeister is serving in this ... fills the position. As CBHS,s top ...
Cached Biology Technology:CU method projected to meet DOE cost targets for solar thermal hydrogen fuel production 2Regional Healthcare Management Firm Goes National 2
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... subsidiary, 3D-ID LLC, a company engaged in biometric identification ... biometrics technology portion of the recently awarded TIES (Technical ... of the Army. 3D-ID LLC has a ... law enforcement and security agencies. Gino ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... to drugs, alcohol and tobacco in utero is bad ... have been hard to tease out in humans. Often ... factors like poverty can also influence brain development. ... brain scans, led by Childrens Hospital Boston neurologist Michael ...
... scientists are now flying through springtime Arctic pollution to ... summertime sea ice is melting - faster than predicted. ... university colleagues in Fairbanks, Alaska, to conduct the study ... our eyes, said A.R. Ravishankara, director of the chemistry ...
... Endometriosis is a poorly understood condition that incapacitates and affects ... world. In the US, it affects approximately six million women ... year. It is a chronic painful disease which occurs ... in the area of the ovaries and fallopian tubes, but ...
Cached Biology News:Your baby's brain on drugs (and alcohol and tobacco) 2NOAA aircraft to probe arctic pollution 2New study finds uncontrollable stress worsens symptoms of endometriosis 2New study finds uncontrollable stress worsens symptoms of endometriosis 3
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
... pleased to offer the ATTO-TAG series ... of primary amines. Developed by Novotny ... ATTO-TAG reagents are similar to the ... and anthracene-2,3-dicarboxaldehyde, all of which are ...
...
... pleased to offer the ATTO-TAG series ... of primary amines. Developed by Novotny ... ATTO-TAG reagents are similar to the ... and anthracene-2,3-dicarboxaldehyde, all of which are ...
Biology Products: